Paris—Dentons’ Paris Partner Pascale Poupelin advised Laboratoire Glaxosmithkline (GSK), a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company, in proceedings before the French Supreme Administrative Court (Conseil d’Etat) aimed at invalidating the French Minister of Health and Social Security decision.

On 24 May 2012, the French Minister of Health and Social Security issued a decision that prevented the anti-cancer medicine Benlysta— produced by GSK—from appearing in a list of medicines reimbursed by the French social security system.

This decision was invalidated by the French Supreme Court, thus enabling patients to benefit from this second line treatment should standard treatment failure occur. 

This unprecedented decision is a tremendous success for Partner Pascale Poupelin as well as the Dentons Paris Life Sciences group.

About Dentons

Across over 80 countries, Dentons helps you grow, protect, operate and finance your organization by providing uniquely global and deeply local legal solutions. Polycentric, purpose-driven and committed to inclusion, diversity, equity and sustainability, we focus on what matters most to you. www.dentons.com